CLDN6: From Traditional Barrier Function to Emerging Roles in Cancers
Open Access
- 14 December 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (24) , 13416
Abstract
Claudins (CLDNs) are the most important tight junction proteins, which are mainly expressed in endothelial cells or epithelial cells in a tissue-specific manner. As a member of the CLDNs family, CLDN6 is highly expressed in fetal tissues such as the stomach, pancreas, lung, and kidney, but is not expressed in corresponding adult tissues. The expression of CLDN6 is regulated by a variety of factors, including but not limited to stimuli and transcription factors, DNA methylation, and post-translational modifications. CLDN6 has been found to have a key role in the formation of barriers, especially the lung epithelial barrier and the epidermal permeability barrier (EPB). Importantly, the roles of CLDN6 in cancers have gained focus and are being investigated in recent years. Strong evidence indicates that the altered expression of CLDN6 is linked to the development of various cancers. Malignant phenotypes of tumors affected by CLDN6 include proliferation and apoptosis, migration and invasion, and drug resistance, which are regulated by CLDN6-mediated key signaling pathways. Given the important role in tumors and its low or no expression in normal tissues, CLDN6 is an ideal target for tumor therapy. This review aims to provide an overview of the structure and regulation of CLDN6, and its traditional barrier function, with a special emphasis on its emerging roles in cancers, including its impact on the malignant phenotypes, signal-modulating effects, the prognosis of tumor patients, and clinical applications in cancers.Keywords
Funding Information
- National Natural Science Foundation of China (82072935)
- Natural Science Foundation of Jilin Province (20210101329JC)
This publication has 87 references indexed in Scilit:
- Gene silencing of claudin-6 enhances cell proliferation and migration accompanied with increased MMP-2 activity via p38 MAPK signaling pathway in human breast epithelium cell line HBL-100Molecular Medicine Reports, 2013
- Claudin-6: a novel receptor for CPE-mediated cytotoxicity in ovarian cancerOncogenesis, 2012
- Distinct expression pattern of claudin‐6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomasHistopathology, 2012
- Claudin-6 is a Nonspecific Marker for Malignant Rhabdoid and Other Pediatric TumorsAmerican Journal of Surgical Pathology, 2012
- Treatment of breast cancer cells with DNA demethylating agents leads to a release of Pol II stalling at genes with DNA-hypermethylated regions upstream of TSSNucleic Acids Research, 2011
- Role of Estrogen Receptor-α in the Regulation of Claudin-6 Expression in Breast Cancer CellsJournal of Breast Cancer, 2011
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- Effect of claudins 6 and 9 on paracellular permeability in MDCK II cellsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2008
- Claudin-6 and Claudin-9 Function as Additional Coreceptors for Hepatitis C VirusJournal of Virology, 2007
- Role of the Cldn6 Cytoplasmic Tail Domain in Membrane Targeting and Epidermal Differentiation In VivoMolecular and Cellular Biology, 2006